Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Capital Expenditures (2020 - 2025)

Rapid Micro Biosystems' Capital Expenditures history spans 6 years, with the latest figure at -$621000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures rose 38.88% year-over-year to -$621000.0; the TTM value through Sep 2025 reached $345000.0, up 29.21%, while the annual FY2024 figure was $309000.0, 30.25% down from the prior year.
  • Capital Expenditures for Q3 2025 was -$621000.0 at Rapid Micro Biosystems, down from $366000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.8 million in Q2 2022 and bottomed at -$5.4 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $319000.0 (2025), against an average of $175473.7.
  • The largest annual shift saw Capital Expenditures skyrocketed 640.0% in 2021 before it tumbled 3807.69% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $706000.0 in 2021, then plummeted by 860.34% to -$5.4 million in 2022, then surged by 104.45% to $239000.0 in 2023, then increased by 17.57% to $281000.0 in 2024, then tumbled by 321.0% to -$621000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPID's Capital Expenditures are -$621000.0 (Q3 2025), $366000.0 (Q2 2025), and $319000.0 (Q1 2025).